2Strober W, Fuss IJ, Blumberg RS. The immunology of mueosal models of inflammation [ J ]. Annu Rev Immuno1,2002 ,20 (4) :495 - 549.
3Bouma G, Strober W. The immunological and genetic basis of inflam- matory bowel disease [ J ]. Nat Rev Immuno1,2003,3 ( 7 ) :521 - 533.
4Xu D, Jiang HR, Kewin P, et al. IL - 33 exacerbates antigen - induced arthritis by activating mast cells [ J ]. Proc Nail Acad Sci USA, 2008, 105 (31) :10913 - 10918.
5Smith DE. IL - 33 : a tissue derived cytokine pathway involved in aller- gic inflammation and asthma [ J ]. Clin Allergy, 2010,40 ( 2 ) : 200 - 208.
6Miller AM, Liew FY. The IL - 33/ST2 pathway - A new therapeutic target in cardiovascular disease [ J ]. Pharmacol Ther, 2011,131 (2) : 179 - 186.
7Yuan FL, Li X, Lu WG, et al. IL - 33 : a promising therapeutic target for rheumatoid arthritis[ J ]. Expert Opin Ther Targets, 2011,15 (5) : 529 - 534.
8Milovanovic M, Volarevic V, Radosavljevicic G, et al. IL - 33/ST2 axis in inflammation and immunopathology [ J ]. Immunol Res, 2012,52 (1 -2) :89 -99.
9Smith DE. The biological paths of IL - 1 family members IL - 18 and IL-33[ J]. J Leukoc Biol,2011,89(3) :383 -392.
10Szanto S, Aleksza M, Mihaly E, et al. Intracytoplasmic cytokine expres- sion and T cell subset distribution in the peripheral blood of patients with ankylosing spondylitis [ J ]. J Rheumatol, 2008,35 ( 12 ) : 2372 - 2375.
